Science Highlights

7 November 2022

New fluorescent tools to evaluate the therapeutic potential of phytocannabinoids

Cannabinoid receptors, CB1 and CB2 are two extensively studied targets of the GPCR family for the treatment of numerous conditions, including inflammatory diseases, autoimmune disorders, pain, […]
26 July 2022

Celtarys Adenosine Receptor fluorescent ligands as potent tools for the study of cancer specific GPCRs

The ONCOMET group from the Health Research Institute of Santiago led by Dr. Miguel Abal has published an interesting article showing tumor and stromal-specific genetic signatures […]
6 April 2022

New GLP1 Receptor fluorescent probes LUXendins developed by our collaborators Johannes Broichhagen and David J. Hodson

The glucagon-like peptide-1 receptor (GLP1R), expressed in peripheral tissues and brain, is known to be involved in several metabolic and inflammatory processes. Despite its clear interest […]
3 February 2022

Celtarys Research Adenosine A3 Receptor fluorescent ligand as a new tool for the study of non-orthosteric interactions

The group led by Dr. Eddy Sotelo at the University of Santiago de Compostela, in collaboration with the Uppsala University, has published a new article exploring […]
28 December 2021

Celtarys exclusive fluorescent ligands for cannabinoid receptors used to analyze binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors

Don’t miss the new article by Dr. Gemma Navarro and Dr. Rafael Franco about cannabinoid CB1 and CB2 receptors signaling. They have successfully used CELT-335, one […]
14 September 2021

Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia

Impressive paper published in Nature journal tackling allosteric modulation of adenosine A1 receptor (A1R) as a promising therapeutic approach of non-opioid analgesic agents to treat neuropathic pain. […]
31 August 2021

Trends in kinase drug discovery: targets, indications and inhibitor design

Abstract: The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer therapy and heralded the emergence of kinase inhibitors as a key […]